Patient Capital Management, a Baltimore-based investment firm, identified UnitedHealth Group Incorporated as a key contributor to its third-quarter 2026 performance in its latest investor letter. The fund highlighted the healthcare company's position in an early-stage earnings recovery, projecting mid-teens compound growth for the next several years across most economic environments. This assessment comes as UnitedHealth Group shares closed at $379.30 on October 09, 2026, trading within a 52-week range of $255.97 to $461.62.
The Patient Opportunity Equity Strategy outperformed the S&P 500 during the latest quarter, gaining 4.32%. Year-to-date, the strategy is up 14.93%, compared to the S&P 500's 12.75% gain. The firm noted that while the market shows resilience, rate increases present both risks and opportunities. It views the current environment as part of a long bull run extending since March 2009, during which the S&P has compounded at 16.9% per year. Despite persistent investor skepticism regarding rising valuations and the durability of the AI revolution, strong corporate earnings suggest potential upside.
In its Q3 2026 letter, Patient Capital specifically addressed its holdings in UnitedHealth Group and Royalty Pharma. The firm stated that both companies have been significant contributors to the fund's performance for the year, yet it continues to favor the risk-reward profile of each. The letter described UnitedHealth's management team as excellent and positioned the company's earnings trajectory favorably. "For the next few years, earnings should grow in the mid-teens in most environments," the letter read, noting that both holdings add ballast to the portfolio.
UnitedHealth Group Incorporated maintains a market capitalization of $340.46 billion. Over the past month, its shares declined by 1.11%, while gaining 5.75% over the trailing 52-week period. According to data from Insider Monkey, UnitedHealth Group ranks 14th on a list of the 40 most popular stocks among hedge funds. At the end of the second quarter, 143 hedge fund portfolios held shares in the company, an increase from 130 portfolios in the prior quarter.
The firm's broader analysis suggests that while UnitedHealth Group offers value, certain artificial intelligence stocks may provide greater upside potential with less downside risk. Earlier coverage noted that UnitedHealth's forward P/E has fallen sharply, raising questions about whether the market has already priced in recent operational troubles. The strategy's portfolio remains concentrated in its top 10 holdings, reflecting a disciplined approach to valuation and risk management amidst market volatility.